Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07804186 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

Name: Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma — clinical trial record (NCT07804186)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorIDEAYA Biosciences

Started2026-09

View on ClinicalTrials.gov ↗

This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)

Trial Details

NCT Number	NCT07804186
Lead Sponsor	IDEAYA Biosciences
Conditions	Uveal Melanoma
Enrollment	450 participants
Start Date	2026-09
Primary Completion	2034-03 (estimated)
Study Completion	2034-04 (estimated)
Updated on ClinicalTrials.gov	2026-09-04